Overview

Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis

Status:
Completed

Trial end date:
2012-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether nabilone (Cesamet) when used as an adjunctive agent with gabapentin (Neurontin) provides significantly improved pain relief over gabapentin alone for the management of neuropathic pain in MS.

Phase:

Phase 4

Details

Lead Sponsor:

University of Manitoba

Collaborators:

Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.

Treatments:

Dronabinol
Gabapentin
Nabilone